

## News Release

Lonza Group Ltd  
Muenchensteinerstrasse 38  
4002 Basel, Switzerland  
[www.lonza.com](http://www.lonza.com)

### **Lonza to Expand Cytotoxic Manufacturing to Serve Growing Oncology API Market**

Basel, Switzerland, 12 May 2011 – Lonza today announced plans to invest CHF 24 million to expand cytotoxic manufacturing capabilities in Visp, Switzerland. Cytotoxic APIs are commonly used in oncology therapeutics, which represent one of the fastest growing segments of the pharma and biotech industry.

Lonza currently operates high potency GMP laboratory suites on gram-scale. The investment will add multi-kilogram scale cytotoxic production capacity which enables Lonza to offer clinical and commercial production of cytotoxics – all within one dedicated facility. These enhanced fermentation and chemical capabilities, along with existing bioconjugation expertise, will help Lonza to comprehensively address its customers cytotoxic manufacturing challenges.

“This investment speeds our efforts to establish the Lonza Visp site as a Center of Excellence for High Potency Manufacturing,” said Stefan Stoffel, Head of Lonza’s Chemical Manufacturing Business Unit. “With the anticipated expansion to be completed in the second quarter of 2012, Lonza Visp will offer a fully integrated end-to-end development and manufacturing solution for a wide-range of technologies, including highly active pharmaceutical ingredients (HAPIs), cytotoxics, peptides and antibody drug conjugates (ADCs).”

The new facility will provide the necessary production lines to secure API supply and meet the regulatory requirements of the coming decade with strict focus on safe handling of compounds with low occupational exposure limits (OEL) to ensure employee and environmental safety. Lonza’s investment allows its customers to capitalize on the unique infrastructure of the Visp site and avoid investment in expertise, assets, and infrastructure required to work with these highly potent products in a highly regulated environment.

Currently, cytotoxic projects are being initiated within Visp’s state-of-the-art GMP laboratory suites. Upon completion of the expansion, Lonza can smoothly transition customer projects for scale-up in the new manufacturing facility.

#### **About Lonza**

Lonza is one of the world’s leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2010, the company had sales of CHF 2.68 billion. Further information can be found at <http://www.lonza.com>.

**For further information**

Lonza Group Ltd  
Head of Corporate Communications  
Dominik Werner  
Tel +41 61 316 8798  
Fax +41 61 316 9798  
[dominik.werner@lonza.com](mailto:dominik.werner@lonza.com)

Lonza Group Ltd  
Investor Relations  
Dirk Oehlers  
Tel +41 61 316 8540  
Fax +41 61 316 9540  
[dirk.oehlers@lonza.com](mailto:dirk.oehlers@lonza.com)

Lonza Group Ltd  
Media Relations  
Melanie Disa  
Tel +1 201 316 9413  
Fax +1 201 696 3533  
[melanie.disa@lonza.com](mailto:melanie.disa@lonza.com)